Q32 Bio (QTTB) Cash & Equivalents (2017 - 2026)

Q32 Bio's Cash & Equivalents history runs 10 years deep, the most recent figure standing at $50.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 22.5% year-over-year to $50.8 million; the TTM figure through Mar 2026 stood at $50.8 million (down 22.5% YoY), while the FY2025 annual figure was $48.3 million, down 38.05% from the prior year.
• Cash & Equivalents was $50.8 million for Q1 2026 at Q32 Bio, up from $48.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $248.1 million in Q1 2022 to a low of $20.1 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $74.3 million across 5 years, with a median of $50.8 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 88.62% in 2023, then surged 386.94% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $34.0 million in 2022, then slipped by 24.62% to $25.6 million in 2023, then surged by 204.35% to $78.0 million in 2024, then slumped by 38.05% to $48.3 million in 2025, then increased by 5.08% to $50.8 million in 2026.
• The last three Cash & Equivalents figures came in at $50.8 million (Q1 2026), $48.3 million (Q4 2025), and $49.0 million (Q3 2025), per Business Quant data.